The two grants awarded will support DiamiR's development of microRNA diagnostics for mild cognitive impairment, Alzheimer's disease, and Rett syndrome.
The project, coordinated by Jena University Hospital and expected to run for five years, aims to address resistance mechanisms in Gram-negative pathogens.
The test will be designed to run on a portable device that can ultimately be rolled out to point-of-need settings such as doctors' offices and workplaces.
The scientists received backing in the form of a €2.4 million EU grant this month and have founded a company, called Biopix-T, to commercialize the platform.
